Ally Bridge Group is a global life science-dedicated investment firm focusing on both private and public equity strategies across the healthcare industry. The firm invests across various stages, from Series A to late-stage rounds, with a particular emphasis on Series B to D investments. Ally Bridge Group's portfolio spans a wide range of healthcare sectors, including biotechnology, medical devices, and digital health.
Notable portfolio companies include Grail, Imperative Care, and Transcarent. The firm leverages its global knowledge and understanding of value across private and public markets to deliver superior returns. Ally Bridge Group offers a unique perspective by bridging the gap between private and public markets, providing valuable insights and support to its portfolio companies throughout their growth journey.
Ally Bridge Group - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Total Investments40
Current Portfolio Count32
Total Portfolio Exits0
Top Investment Stages
Series B8 (27.6%)
Series D6 (20.7%)
Series Unknown6 (20.7%)
Series C5 (17.2%)
Post Ipo Equity4 (13.8%)
Stage Mix
Series B 28%Series D 21%Series Unknown 21%Series C 17%Post Ipo Equity 14%
Concentration shown as share of disclosed investments by stage.
Ally Bridge Group - Classification
- NAICS
- 520000Finance and Insurance
- 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
- 523900Other Financial Investment Activities
- 523990All Other Financial Investment Activities
- 523999Miscellaneous Financial Investment Activities
- SIC
- 6700Holding And Other Investment Offices
- 6720Investment Offices
- 6722Management Investment Offices, Open-end
Show 5 more industry codes
- NAICS
- 525000Funds, Trusts, and Other Financial Vehicles
- 523910Miscellaneous Intermediation
- SIC
- 6000Depository Institutions
- 6790Miscellaneous Investing
- 6799Investors, Not Elsewhere Classified